Mylan: In EpiPen Controversy, Shades of Valeant

If we learned anything from Valeant Pharmaceuticals International ( VRX )--besides the fact that using a captive pharmacy to get around insurance companies --its that raising drug prices creates a lot of bad press and invites a ton of scrutiny. That's what Mylan ( MYL ) faces now that its jacked up the price of its EpiPen. While the controversy probably won't hurt Mylan's earnings, it could have an impact on the price investors are willing to pay for the stock. Citigroup's Liav Abraham and Eugene Kim explain: